Sol-Gel Technologies Ltd. SLGL
Set alert
As of Nov 2, 10:26 AM ET
- YTD
- +58.31%
- 1 year
- +93.36%
- Open
- 67.29
- Prev close
- 68.35
- Mkt cap
- 218.51M
- Vol
- 8.29K
- Avg vol
- 53.20K
- EPS
- -5.61
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 65.74
- High
- 67.29
- Forward P/E
- -3.44
- Beta
- 1.60
- Short ratio
- 0.59
- Inst. own
- 19.35%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 16, 2024
- 50-d avg
- 0.55476
- 200-d avg
- 0.70915
- 1y target
- 5.00
Key statistics
- Market cap
- 45.97M
- Enterprise value
- -14.73M
- Trailing P/E
- 0.00
- Forward P/E
- -3.44
- PEG ratio
- 0.00
- Price / sales
- 7.01
- Price / book
- 1.19
- EPS (TTM)
- -0.34
- Beta
- 1.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -227.40%
- Revenue (TTM)
- 6.56M
- Revenue growth
- 814.60%
- Free cash flow
- -12.43M
- Total cash
- 30.47M
- Total debt
- 1.39M
- Return on equity
- -35.85%
- Shares outstanding
- 27.86M
- Short % of float
- 0.31%
- 50-day average
- 0.55476
- 200-day average
- 0.70915
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 5.00
- Target (high)
- 6.00
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 16, 2024
Expected Aug 16, 2024. Consensus EPS estimate -0.11.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | -0.13 | -0.01 | +0.12 | +92.31% |
| Aug 16, 2024 | Jun 1, 2024 | -0.20 | 0.07 | +0.27 | +135.00% |
| Aug 16, 2024 | Jun 1, 2024 | -0.20 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.15 | -0.23 | -0.08 | -53.33% |
| May 20, 2024 | Mar 1, 2024 | -0.15 | — | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -0.16 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 2024 | Raymond James | down | Strong Buy | Outperform |
| May 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 20, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 11, 2023 | Raymond James | main | Strong Buy | Strong Buy |
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- sol-gel.com
News
- HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $110 Price Target
- This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Cantor Fitzgerald Initiates Coverage On Sol-Gel Technologies with Overweight Rating
- Sol-Gel Technologies Q2 EPS $(1.13) Beats $(2.31) Estimate, Sales $591.000K Beat $75.000K Estimate
- HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $110 Price Target
- This Nucor Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
- This Take-Two Interactive Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Mizuho Initiates Coverage On Sol-Gel Technologies with Outperform Rating, Announces Price Target of $285
- Sol-Gel Technologies Q1 EPS $(1.31) Beats $(1.84) Estimate, Sales $108.000K Miss $900.000K Estimate
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
Your note
Sign in to keep a note on SLGL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Phoenix Holdings Ltd. | 8.87% | 2,470,192 | 4.08M | Sep 29, 2024 |
| Migdal Insurance & Financial Holdings Ltd. | 4.41% | 1,227,548 | 2.03M | Sep 29, 2024 |
| Harel Insurance Investments & Financial Services Ltd. | 3.30% | 920,333 | 1.52M | Sep 29, 2024 |
| Yelin Lapidot Holdings Management Ltd. | 0.82% | 229,178 | 378.14K | Sep 29, 2024 |
| Prosperity Wealth Management, Inc. | 0.59% | 163,400 | 269.61K | Sep 29, 2024 |
| Raymond James Financial Services Advisors, Inc. | 0.32% | 88,461 | 145.96K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 13,406 | 22.12K | Oct 30, 2024 |